Roth Capital Upgrades DepoMed Inc (DEPO) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
DepoMed (DEPO) Price Target Raised to $22 at Janney
January 16, 2015 3:31 PM ESTJanney Capital maintained a Buy rating on DepoMed Inc (NASDAQ: DEPO) and raised its price target to $22.00 (from $18.50). Yesterday DepoMed announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals for $1.05 billion. Analyst Chiara Russo updated his revenue model to reflect the additional... More
DepoMed (DEPO) to Acquire NUCYNTA Rights from Janssen (JNJ)
January 15, 2015 4:05 PM ESTDepoMed (Nasdaq: DEPO) announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. NUCYNTA (tapentadol) oral solution is an approved oral form of tapentadol... More
